Sangamo Therapeutics, Inc.
corporate_fare Company Profile
Sangamo Therapeutics, Inc. (OTC:SGMOQ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for SGMOQ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 7/10. Across its 6 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for SGMOQ spans 8-K.
Recent high-impact activity:
- Sangamo Posts $138.5M Cash After $161M Asset Sales in September MOR
- Completes $50M Asset Sale to Eli Lilly; Reports July Operating Loss of $11.17M in Bankruptcy
- Sangamo Inks Definitive $211M Asset Sale to PTC for Fabry Gene Therapy
- Sangamo Selects PTC and Lilly as Winning Bidders in $163.55M Asset Auction
- Sangamo Therapeutics: Court Clears Bidding Procedures as Nasdaq Denies Continued Listing
Financial Snapshot
Short Interest & Short Volume
4.89 days to coverFINRA reported short interest of 8,348,367 shares in SGMOQ as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 32.3% of SGMOQ volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.